Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Women's knee injury risk: new study probes hormone link

NCT ID NCT05177549

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how hormones and birth control pills affect knee ligament looseness in healthy women. Researchers measured knee laxity in 45 women at two points in their menstrual cycle, comparing those on hormonal contraceptives to those not. The goal was to better understand why women have a higher risk of ACL knee injuries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Jun 2022

Finished

Aug 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Woman between 18 and 40 years old * No history of surgery of the 2 lower limbs * No change in contraceptive method in the last 6 months * Signature of the informed consent * Affiliation to the social security system * To be at Day 14 of her menstrual cycle (+/-1 day) (the first day of the cycle (Day1) being considered as the first day of the menstrual period), except for those on micro-progestative contraception not regulated By inclusion group: \- For women without hormonal contraception: No method of contraception Or a copper intrauterine device Regular cycles of 26 to 33 days \- For women on estrogen-progestin contraception: Correct use of the estrogen-progestin pill according to the MA Or wearing a vaginal ring according to the MA protocol Or wearing a contraceptive skin patch according to the MA protocol Regular cycles of 26 to 33 days \- For women on micro-progestin contraception : Continuous use of the micro-progestogen pill Or wearing a subcutaneous hormonal implant, Exception: women on micro-progestin contraception who are not regulated: * They may have an irregular cycle or no cycle to be included * They can be included on any day if they have no cycle Exclusion Criteria: * Pregnancy or breastfeeding in progress * Hormonal intrauterine device or injectable contraception * Menopause (defined as no menstruation for one year) * Surgery: tubal ligation, oophorectomy, adnexectomy, hysterectomy * History of microcrystalline or infectious pathology localized to the knee * History of systemic or localized inflammatory joint disease of the knee * History of fracture, severe sprain or dislocation of the knee joint * History of osteoarticular or congenital diseases that may lead to laxity (Marfan syndrome, trisomy 21, Ehlers-Danlos syndrome...) * Sign of hyperlaxity evaluated by a Beighton score higher than 4 (see appendix) * BMI \> 25 * Daily alcohol consumption above the thresholds recommended by Public Health in France (more than 2 glasses per day) * Woman unable to understand the protocol * Intense or unusual physical exercise during the last 72 hours (e.g.: marathon, triathlon, competitive cycling race...) * Woman under guardianship, curatorship or deprived of liberty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ligament; laxity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Nice

    Nice, 06300, France